A testing dose was unnecessary, Novartis believed, given that valsartan 320mg (160mg twice a day) had been tested in heart failure and with a 1:1 ratio with sacubitril. "I had nothing to learn ...

The drug was developed over 20 years ago by Novartis and since then has been very frequently prescribed to treat patients with high blood pressure. Valsartan has been also used to prevent heart ...

Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms of heart failure. MSN submitted an Abbreviated New ...

That said, a key combination patent on the drug—known generically as sacubitril and valsartan—is set to expire in July, with Novartis warning in a recent earnings presentation that the drug ...

The company has received final approval from the US Food & Drug Administration (USFDA) for Sacubitril and Valsartan Tablets ... therapeutically equivalent to Novartis's Entresto tablets.

(JAMA Cardiology) A federal judge rejected Novartis' motion to declare as unlawful the FDA approval of a generic sacubitril/valsartan (Entresto) from MSN Laboratories. For a minor nondisabling ...